Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Journal of Hematology & Oncology, 05/01/2012
Clinical Article
Raza A et al. – The tolerability and activity profile of ezatiostat co–administered with lenalidomide supports the further development of ezatiostat in combination with lenalidomide in myelodysplastic syndrome (MDS) and also encourages studies of this combination in other hematologic malignancies where lenalidomide is active.



